Myasthenia Gravis Treatment Market Research, 2032
The global myasthenia gravis treatment market was valued at $1.7 billion in 2022, and is projected to reach $3.1 billion by 2032, growing at a CAGR of 6.5% from 2023 to 2032. Myasthenia gravis (MG) is a rare autoimmune disorder that affects the neuromuscular junction, causing muscle weakness and fatigue. The disease can occur in individuals of all ages and is more commonly diagnosed in women under the age of 40 and men over the age of 60. Myasthenia gravis can significantly impact the daily life of affected individuals, leading to limitations in mobility, difficulty carrying out activities of daily living, and a negative impact on mental health and quality of life. However, there are several treatment options available for myasthenia gravis such as cholinesterase inhibitors, immunosuppressants, monoclonal antibodies, intravenous immunoglobulin (IVIg).
Market Dynamics
Growth & innovations in the pharmaceutical industry for the manufacturing of myasthenia gravis drugs owing to massive pool of health-conscious consumers, creates an opportunity for the myasthenia gravis treatment market. The major factors driving the growth of market are increasing prevalence of myasthenia gravis, awareness regarding early diagnosis and adoption of novel treatment options for myasthenia gravis. The increasing prevalence of myasthenia gravis worldwide is one of the primary drivers for the growth of the myasthenia gravis treatment market. For instance, according to the Myasthenia Gravis Foundation of America, approximately 20 out of 100,000 people in the U.S. are affected by myasthenia gravis, and the disease is more common in women than men. Moreover, the incidence of myasthenia gravis is increasing globally, which is expected to drive the demand for effective treatments for the disease.
Further, myasthenia gravis treatment market is witnessing significant growth owing to the increasing focus of pharmaceutical companies on the development of novel drugs for the treatment of the disease. Several drugs, including monoclonal antibodies and immunosuppressants, are being developed and tested for their efficacy in treating myasthenia gravis. Moreover, the increasing investment in research and development by pharmaceutical companies is expected to drive the myasthenia gravis treatment market opportunity.
The growing awareness about myasthenia gravis among patients and healthcare professionals is also contributing to the rise in demand for effective treatments. As more people become aware of the symptoms and risks associated with myasthenia gravis, they are more likely to seek diagnosis and treatment. In addition, healthcare professionals are also becoming more knowledgeable about the disease and its treatment options, leading to an increased demand for effective treatments.
Moreover, government initiatives to improve healthcare infrastructure and increase awareness about myasthenia gravis are also driving market growth. Many governments around the world are investing in programs to improve diagnosis and treatment of myasthenia gravis, which is expected to further increase the demand for effective treatments.
The growth of the myasthenia gravis treatment market is expected to be driven by emerging markets, due to availability of improved healthcare infrastructure, increase in unmet healthcare needs, rise in prevalence of autoimmune diseases, and surge in demand for novel drugs for management of myasthenia gravis. Furthermore, the healthcare industry in emerging economies is developing at a significant rate, owing to rise in demand for enhanced healthcare services, significant investments by government to improve healthcare infrastructure, and development of the medical tourism industry in emerging countries.
Various organizations along with government are counselling people regarding the autoimmune diseases. E-commerce (electronic commerce) has become a vital tool for small and large businesses globally, owing to rise in preference of consumers for online shopping over traditional purchasing methods. Various animations through health apps to educate people regarding myasthenia gravis and usage of medications have contributed toward the myasthenia gravis treatment market growth.
The demand for effective intravenous immunoglobulin (IVIg) and monoclonal antibodies is not only limited to developed countries but is also being witnessed in the developing countries, such as China, Brazil, and India, which fuel the growth of the market. Moreover, increase in promotional activities by manufacturers and growth in awareness for proper treatment medications for myasthenia gravis among the general population is expected to fuel their adoption in the near future.
However, myasthenia gravis treatment market is the side effects associated with the drugs used for the treatment of the disease. Drugs such as corticosteroids and immunosuppressants are associated with several side effects, including increased risk of infection, weight gain, mood changes, and gastrointestinal problems, which can impact patient compliance and restrict market growth.
The outbreak of COVID-19 has disrupted workflows in the healthcare sector around the world. The delay in diagnosis and treatment of myasthenia gravis during the pandemic had a significant impact on patient outcomes. During the pandemic, patients with non-emergency conditions such as myasthenia gravis were often unable to receive timely medical attention. This delay in diagnosis and treatment can lead to disease progression and worsened symptoms, impacting the quality of life of myasthenia gravis patients.
Moreover, the pandemic disrupted the supply chains of drugs and medical devices worldwide, leading to shortages and delays in the delivery of myasthenia gravis treatments. This can impact patient access to treatments, particularly in regions with limited healthcare infrastructure. Additionally, companies operating in the myasthenia gravis treatment market were impacted financially by the pandemic-induced disruptions, with revenue growth being limited due to supply chain issues.
The COVID-19 pandemic also increased the risk of myasthenic crisis, respiratory failure, and permanent pulmonary damage in myasthenia gravis patients due to their suppressed immune systems. This further highlights the need for timely diagnosis and treatment for myasthenia gravis patients, particularly during a pandemic.
Segmental Overview
The myasthenia gravis treatment market is segmented into drug class, age group, distribution channel and region. On the basis of drug class, the market is categorized into monoclonal antibodies, intravenous immunoglobulin and others. On the basis of age group, the market is segregated into below 55 years and above 55 years. On the basis of distribution channel, the market is segregated into hospital pharmacies, drug stores and retail pharmacies and online providers. Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, India and rest of Asia-Pacific), and LAMEA (Latin America and Middle East & Africa).
By Drug Class
The others segment accounted for largest myasthenia gravis treatment market size in terms of revenue in 2022, owing to rise in adoption of drugs such cholinesterase inhibitors and immunosuppressants to manage the symptoms of myasthenia gravis. The monoclonal antibodies segment accounted for highest CAGR during the forecast period, owing to effectiveness of monoclonal antibody in treating myasthenia gravis and rise in number of regulatory approvals.
By Age Group
The below 55 years segment accounted for largest myasthenia gravis treatment market size in 2022 and is expected to register highest CAGR owing to rise in prevalence of autoimmune disease in people aged below 55 years.
By Distribution Channel
The drug stores and retail pharmacies segment accounted for largest myasthenia gravis treatment market share in 2022 and is projected to register the highest CAGR owing to the accessibility of retail pharmacies everywhere and the large chain of distribution networks. In addition, drug stores and retail pharmacies play important role in providing education and counseling to patients about their medications, potential side effects, and the importance of adhering to their treatment plans.
By Region
The myasthenia gravis treatment market is analyzed across North America, Europe, Asia-Pacific, and LAMEA. North America accounted for the largest myasthenia gravis treatment market share in terms of revenue in 2022, owing to high prevalence of myasthenia gravis, rise in diagnosis for autoimmune diseases, availability of advanced healthcare infrastructure and presence of major players offering novel therapeutics, thus is expected to drive the myasthenia gravis treatment market. However, Asia-Pacific is anticipated to witness notable growth, owing to increasing number of autoimmune diseases, increase in awareness campaign regarding autoimmune diseases & available treatment options and rise in investments for development of effective treatment options for myasthenia gravis. Upsurge in healthcare expenditure in the emerging economies is anticipated to offer lucrative opportunities for the market expansion and drive the myasthenia gravis treatment market forecast.
Presence of several major players, such as F. Hoffmann-La Roche Ltd, AstraZeneca, CSL Limited, Grifols, S.A., and advancement in manufacturing technology for development of effective treatment options for autoimmune disease in the region is expected to drive the growth of myasthenia gravis treatment industry. In addition, various private organizations organize educating camps for awareness of autoimmune diseases and treatment options available across the globe is expected to drive growth of this market. Furthermore, presence of well-established healthcare infrastructure, and rise in adoption rate of new treatment options such as intravenous immunoglobulins (IVIg) for myasthenia gravis treatment are expected to drive the market growth. Furthermore, various product approval and strategic alliance as key strategy adopted by the key players in this region further boost the growth of the market. For instance, in November 2020, Grifols adopted strategic with Egyptian government to boost plasma-derived medicines self-sufficiency in the Middle East and Africa countries.
Asia-Pacific expected to grow at the highest rate during the forecast period. The market growth in this region is attributable to presence of key players in the region. Moreover, rise in adoption of various such as monoclonal antibodies for myasthenia gravis are expected to drive the growth of the market. In India significant number of efforts have been taken toward spread of awareness related to better understanding of autoimmune diseases such as myasthenia gravis. Furthermore, the Indian government has implemented several initiatives to support the growth of the healthcare sector, including increased funding for research and development, improvements to healthcare infrastructure, and the promotion of public-private partnerships. These efforts have helped to create a favorable environment for the growth of the myasthenia gravis treatment market in India and other related healthcare sectors.
Asia-Pacific offers profitable opportunities for key players operating in the myasthenia gravis treatment market, thereby registering the fastest growth rate during the forecast period, owing to the growing infrastructure of industries, rising in spending for autoimmune diseases, as well as well-established presence of domestic companies in the region. In addition, rise in contract manufacturing organizations within the region provides great opportunity for new entrants in this region.
Furthermore, advancements in diagnostic techniques are leading to more accurate and timely diagnosis of myasthenia gravis, which is driving market growth. The most common diagnostic tests for myasthenia gravis include a physical exam, blood tests to detect antibodies, nerve conduction studies, and electromyography (EMG). In recent years, several new diagnostic techniques have been developed that are enabling earlier and more accurate diagnosis of myasthenia gravis medication market.
Competition Analysis
Competitive analysis and profiles of the major players in the myasthenia gravis treatment market, such as F. Hoffmann-La Roche Ltd., AstraZeneca, Novartis AG, Zydus Lifesciences Limited, Bausch Health Companies, Inc., CSL Limited, Grifols, S.A., Octapharma AG, Astellas Pharma Inc., and Kedrion, SpA., are provided in this report. Major players have adopted acquisition, product approval, expansion, strategic alliance, and agreement as key developmental strategies to improve the product portfolio of the myasthenia gravis treatment industry.
Recent Product Approval in Myasthenia Gravis Treatment Market
- In September 2022, Ultomiris (ravulizumab) received approval in Europe for the treatment of adult patients with generalised myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody-positive.
- In April 2023, Global biotechnology leader CSL Behring received the U.S. Food and Drug Administration (FDA) approved a 50mL/10gm prefilled syringe for Hizentra (Immune Globulin Subcutaneous [Human] 20% Liquid).
Recent Acquisition in Myasthenia Gravis Treatment Market
- In April 2022, Grifols a global leader in plasma-derived medicines acquired Tiancheng (Germany) Pharmaceutical Holdings AG, a German company, specialized in innovative hematology and clinical immunology.
- In March 2021, Grifols a global healthcare company, acquired GigaGen Inc., a U.S. biotechnology company specialized in the early discovery and development of recombinant biotherapeutic medicines.
Key Benefits For Stakeholders
- This report provides a quantitative analysis of the myasthenia gravis medication market segments, current trends, estimations, and dynamics of the myasthenia gravis treatment market analysis from 2022 to 2032 to identify the prevailing myasthenia gravis treatment market opportunities.
- The market research is offered along with information related to key drivers, restraints, and opportunities.
- Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
- In-depth analysis of the myasthenia gravis treatment medication market segmentation assists to determine the prevailing market opportunities.
- Major countries in each region are mapped according to their revenue contribution to the global market.
- Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the myasthenia gravis medication market players.
- The report includes the analysis of the regional as well as global myasthenia gravis treatment market trends, key players, market segments, application areas, and market growth strategies.
Myasthenia Gravis Treatment Market Report Highlights
| Aspects | Details |
 Market Size By 2032 | USD 3.1 billion |
 Growth Rate | CAGR of 6.5% |
 Forecast period | 2022 - 2032 |
 Report Pages | 263 |
 By Drug class |
|
 By Age group |
|
 By Distribution channel |
|
 By Region |
|
 Key Market Players | Octapharma AG, Astellas Pharma Inc., F. Hoffmann-La Roche Ltd., Kedrion, SpA, Grifols, S.A., AstraZeneca, CSL Limited, Novartis AG, Bausch Health Companies, Inc., Zydus Lifesciences Limited |
 Other Players | Stryker Corporation |
Analyst Review
This section provides various opinions of top-level CXOs in the global myasthenia gravis treatment market. According to the insights of CXOs, increase in demand for advanced therapeutic options for autoimmune diseases and rise in investments for R&D activities related to autoimmune diseases such as myasthenia gravis, globally is expected to offer profitable opportunities for the expansion of the market. In addition, favorable government initiatives and higher spending for autoimmune diseases have piqued the interest of several companies to develop novel medications.
CXOs further added that rise in expenditure on the development of healthcare infrastructure and availability of various diagnostic tests for myasthenia gravis are expected to boost the growth of myasthenia gravis treatment market. In addition, increase in burden of autoimmune diseases across the globe has resulted in rise in demand for novel treatment options, thus driving the growth of market.
Furthermore, North America accounted for the largest share in terms of revenue in 2022 owing to high prevalence of myasthenia gravis, higher diagnosis rate for myasthenia, and increase in R&D activities for development of novel medications. However, Asia-Pacific is anticipated to witness notable growth owing to increase in awareness campaign regarding autoimmune diseases & available treatment options and rise in investments for development of effective treatment options for myasthenia gravis.
Increase in diagnosis has led to greater awareness of the disease among patients and healthcare professionals and development of novel drugs are the upcoming trends of market.
Drug store and retail pharmacies is the leading distribution channel of Myasthenia Gravis Treatment Market.
North America is the largest regional market for Myasthenia Gravis Treatment.
The global myasthenia gravis treatment market was valued at $1.7 billion in 2022, and is projected to reach $3.1 billion by 2032, growing at a CAGR of 6.5% from 2023 to 2032.
F. Hoffmann-La Roche Ltd., AstraZeneca, Novartis AG, Zydus Lifesciences Limited, Bausch Health Companies, Inc., CSL Limited, Grifols, S.A., Octapharma AG, Astellas Pharma Inc., and Kedrion, SpA. are the top companies to hold the market share in Myasthenia Gravis Treatment.
2022 is the base year of Myasthenia Gravis Treatment.
2023 to 2032 is the forecast period of Myasthenia Gravis Treatment.
Loading Table Of Content...
Loading Research Methodology...
